Table 2.
Participant Characteristic | mEHT | Control | p-Value | |||
---|---|---|---|---|---|---|
106 | (50.5%) | 104 | (49.5%) | |||
HIV Status | Positive | 52 | (49.1%) | 55 | (52.9%) | p = 0.579 |
Negative | 54 | (50.9%) | 49 | (47.1%) | ||
Age Group | <50 years | 52 | (49.1%) | 46 | (44.2%) | p = 0.483 |
≥50 years | 54 | (50.9%) | 58 | (55.8%) | ||
ECOG | 0 | 3 | (2.8%) | 7 | (6.7%) | p = 0.184 |
1 | 103 | (97.2%) | 97 | (93.3%) | ||
Race | African | 98 | (92.5%) | 97 | (93.3%) | p = 0.335 |
Caucasian | 4 | (3.8%) | 1 | (1.0%) | ||
Indian | 0 | (0.0%) | 0 | (0.0%) | ||
Asian | 0 | (0.0%) | 0 | (0.0%) | ||
Mixed Race | 4 | (3.8%) | 6 | (5.8%) | ||
Education | Primary | 45 | (43.3%) | 50 | (49.0%) | p = 0.334 |
Secondary | 55 | (52.9%) | 51 | (50.0%) | ||
Tertiary | 4 | (3.8%) | 1 | (1.0%) | ||
Employment | Unemployed | 83 | (78.3%) | 82 | (78.8%) | p = 0.923 |
Employed | 23 | (21.7%) | 22 | (21.2%) | ||
FIGO | IIB | 40 | (37.7%) | 36 | (34.6%) | p = 0.895 |
Staging | IIIA | 1 | (0.9%) | 1 | (1.0%) | |
IIIB | 65 | (61.3%) | 67 | (64.4%) | ||
Histological Grade | 1 | 7 | (6.9%) | 4 | (4.1%) | p = 0.759 |
2 | 70 | (69.3%) | 67 | (69.1%) | ||
3 | 24 | (23.8%) | 26 | (26.8%) | ||
Tumour Dimensions (cm) | Median | 7 | 7.1 | p = 0.1429 | ||
Min | 2.7 | 1.8 | ||||
Max | 11.7 | 14.87 | ||||
Tumour SUV | Median | 18.07 | 19.26 | p = 0.7769 | ||
Min | 7.01 | 6.07 | ||||
Max | 63.25 | 97 | ||||
HB (g/dL) | Median | 10.9 | 11 | p = 0.9424 | ||
Min | 5.7 | 5.2 | ||||
Max | 16.2 | 16.2 | ||||
Age | Median | 49.2 | 50.6 | p = 0.3665 | ||
Min | 27.3 | 29.2 | ||||
Max | 70.8 | 74.8 | ||||
BMI | Median | 27 | 26.5 | p = 0.3883 | ||
Min | 15 | 15 | ||||
Max | 49 | 41.7 |
Abbreviations: BMI: Body Mass Index; ECOG: Eastern Cooperative Oncology Group; FIGO: Fédération Internationale de Gynécologie et d’Obstétrique; HB: Haemoglobin; HIV: Human Immunodeficiency Virus; mEHT: Modulated Electro-Hyperthermia; SUV: Standard Uptake Value.